Theratechnologies Inc.

NasdaqCM:THTX Stock Report

Market Cap: US$95.6m

Theratechnologies Management

Management criteria checks 3/4

Theratechnologies' CEO is Paul Lévesque, appointed in Apr 2020, has a tenure of 4.75 years. total yearly compensation is $1.90M, comprised of 34.7% salary and 65.3% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $151.34K. The average tenure of the management team and the board of directors is 6.6 years and 4.5 years respectively.

Key information

Paul Lévesque

Chief executive officer

US$1.9m

Total compensation

CEO salary percentage34.7%
CEO tenure4.8yrs
CEO ownership0.2%
Management average tenure6.6yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Paul Lévesque's remuneration changed compared to Theratechnologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Aug 31 2024n/an/a

-US$3m

May 31 2024n/an/a

-US$7m

Feb 29 2024n/an/a

-US$18m

Nov 30 2023US$2mUS$659k

-US$24m

Aug 31 2023n/an/a

-US$29m

May 31 2023n/an/a

-US$36m

Feb 28 2023n/an/a

-US$49m

Nov 30 2022US$2mUS$657k

-US$47m

Aug 31 2022n/an/a

-US$49m

May 31 2022n/an/a

-US$51m

Feb 28 2022n/an/a

-US$35m

Nov 30 2021US$2mUS$639k

-US$32m

Aug 31 2021n/an/a

-US$27m

May 31 2021n/an/a

-US$25m

Feb 28 2021n/an/a

-US$24m

Nov 30 2020US$2mUS$379k

-US$23m

Compensation vs Market: Paul's total compensation ($USD1.90M) is above average for companies of similar size in the US market ($USD641.95K).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.

CEO

Paul Lévesque (60 yo)

4.8yrs

Tenure

US$1,900,415

Compensation

Mr. Paul Lévesque has been President, Chief Executive Officer and Director at Theratechnologies Inc. since April 6, 2020. Mr. Lévesque boasts many years of experience in the pharmaceutical field. After beg...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Lévesque
President4.8yrsUS$1.90m0.16%
$ 151.3k
Philippe Dubuc
Senior VP & CFO8.9yrsUS$654.50k0.034%
$ 32.7k
Jocelyn Lafond
General Counsel & Corporate Secretary17.8yrsUS$468.88k0.0098%
$ 9.4k
Christian Marsolais
Senior VP & Chief Medical Officer8.5yrsUS$656.79k0.032%
$ 30.8k
John Leasure
Global Commercial Officer3.8yrsUS$604.30k0.11%
$ 106.5k
Andre Dupras
Vice President of Human Resources3.7yrsno datano data

6.6yrs

Average Tenure

59.5yo

Average Age

Experienced Management: THTX's management team is seasoned and experienced (6.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul Lévesque
President4.8yrsUS$1.90m0.16%
$ 151.3k
Frank Holler
Independent Chairman3.6yrsUS$65.48k0.13%
$ 124.2k
Roger Guillemin
Member of the Scientific Advisory Boardno datano datano data
George Merriam
Member of the Scientific Advisory Boardno datano datano data
David Clemmons
Member of the Scientific Advisory Boardno datano datano data
Andrew Molson
Independent Director4.3yrsUS$64.00k0.30%
$ 285.8k
Dawn Svoronos
Independent Director11.8yrsUS$141.74k0.24%
$ 230.5k
Steven Grinspoon
Member of the Scientific Advisory Boardno datano datano data
Peter Reiss
Member of the Scientific Advisory Boardno datano datano data
Julian Falutz
Member of the Scientific Advisory Boardno datano datano data
Dale MacCandlish-Weil
Independent Director7.7yrsUS$66.96k0.096%
$ 91.8k
Joseph Arena
Independent Director3.7yrsUS$61.31k0.030%
$ 28.6k

4.5yrs

Average Tenure

67.5yo

Average Age

Experienced Board: THTX's board of directors are considered experienced (4.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 05:05
End of Day Share Price 2025/01/08 00:00
Earnings2024/08/31
Annual Earnings2023/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Theratechnologies Inc. is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZhangBMO Capital Markets U.S. (Historical)
Douglas LoeByron Capital Markets
Dewey SteadmanCanaccord Genuity